We have evaluated the effect of formoterol in 28 patients (20 males and 8 females, mean age 25.4 years) affected by mild or moderate bronchial asthma due to Parietaria allergy. Inhaled formoterol was given at the dosage of 24 mg twice a day for 10 weeks during the pollen season. Patients had to record daily the peak respiratory flow, the severity and the number of asthmatic attacks and the severity of cough. Moreover they had to report the use of additional bronchodilators and the possible side effects. The treatment with formoterol obtained in increase of PEF values from 254 +/- 6.1 to 329 +/- 6.1 l/min in the morning and from 237 +/- 7.1 to 365 +/- 7.1 l/min in the evening. A significant improvement on the number of asthmatic attacks and ...
BACKGROUND: The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a do...
Bronchial hyperresponsiveness (BHR) is a characteristic feature of bronchial asthma, defined as an i...
Background The role of long-acting, inhaled beta(2)-agonists in treating asthma is uncertain. In a d...
<em>Efficacy and safety of long acting 29 agonist formoterol (foradil aerolizer) was investigated in...
The single-dose effect of formoterol racemate and enantiomers on bronchodilatation up to 24 h was de...
Background - The long acting beta(2) agonist formoterol has proved to be an effective bronchodilator...
The aim of the study was to investigate the time of onset and the duration of the bronchodilating ef...
AbstractA number of studies have already demonstrated the clinical effectiveness of formoterol when ...
AbstractThe aim of the study was to investigate the time of onset and the duration of the bronchodil...
Ten subjects with various degrees of asthma severity underwent a three-day trial, with the aim of ev...
BACKGROUND: The long acting beta 2 agonist formoterol has proved to be an effective bronchodilator w...
Long-acting beta(2)-adrenoceptor agonists attenuate the allergen-induced late asthmatic reaction. We...
AbstractWhile short-acting β2-agonists are seen as the cornerstone of treatment as relief medication...
Background: Formoterol is a fast-acting, long-acting beta-agonist. Its on-demand use by outpatients ...
SummaryPurposeThe aim of this study was to demonstrate the equivalent efficacy of inhaled formoterol...
BACKGROUND: The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a do...
Bronchial hyperresponsiveness (BHR) is a characteristic feature of bronchial asthma, defined as an i...
Background The role of long-acting, inhaled beta(2)-agonists in treating asthma is uncertain. In a d...
<em>Efficacy and safety of long acting 29 agonist formoterol (foradil aerolizer) was investigated in...
The single-dose effect of formoterol racemate and enantiomers on bronchodilatation up to 24 h was de...
Background - The long acting beta(2) agonist formoterol has proved to be an effective bronchodilator...
The aim of the study was to investigate the time of onset and the duration of the bronchodilating ef...
AbstractA number of studies have already demonstrated the clinical effectiveness of formoterol when ...
AbstractThe aim of the study was to investigate the time of onset and the duration of the bronchodil...
Ten subjects with various degrees of asthma severity underwent a three-day trial, with the aim of ev...
BACKGROUND: The long acting beta 2 agonist formoterol has proved to be an effective bronchodilator w...
Long-acting beta(2)-adrenoceptor agonists attenuate the allergen-induced late asthmatic reaction. We...
AbstractWhile short-acting β2-agonists are seen as the cornerstone of treatment as relief medication...
Background: Formoterol is a fast-acting, long-acting beta-agonist. Its on-demand use by outpatients ...
SummaryPurposeThe aim of this study was to demonstrate the equivalent efficacy of inhaled formoterol...
BACKGROUND: The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a do...
Bronchial hyperresponsiveness (BHR) is a characteristic feature of bronchial asthma, defined as an i...
Background The role of long-acting, inhaled beta(2)-agonists in treating asthma is uncertain. In a d...